![Deborah A. O’Neil](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Deborah A. O’Neil
Amministratore Delegato presso NovaBiotics Ltd.
Posizioni attive di Deborah A. O’Neil
Società | Posizione | Inizio | Fine |
---|---|---|---|
NovaBiotics Ltd.
![]() NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | Amministratore Delegato | 01/08/2004 | - |
Direttore Tecnico/Scientifico/R&S | 01/08/2004 | - | |
Fondatore | 23/11/2009 | - | |
Leap Confronting Conflict
![]() Leap Confronting Conflict Investment Trusts/Mutual FundsMiscellaneous Leap Confronting Conflict operates as a non-profit organization that provides inspirational conflict management training and support to young people and the professionals working with them. The company was founded on September 8, 1998 and is headquartered in London, the United Kingdom. | Direttore/Membro del Consiglio | 06/07/2017 | - |
Storia della carriera di Deborah A. O’Neil
Formazione di Deborah A. O’Neil
University College London | Doctorate Degree |
Statistiche
Distribuzione geografica
Regno Unito | 4 |
Posizioni
Chief Executive Officer | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Settori
Health Technology | 2 |
Consumer Services | 2 |
Miscellaneous | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 2 |
---|---|
NovaBiotics Ltd.
![]() NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | Health Technology |
Leap Confronting Conflict
![]() Leap Confronting Conflict Investment Trusts/Mutual FundsMiscellaneous Leap Confronting Conflict operates as a non-profit organization that provides inspirational conflict management training and support to young people and the professionals working with them. The company was founded on September 8, 1998 and is headquartered in London, the United Kingdom. | Miscellaneous |
- Borsa valori
- Insiders
- Deborah A. O’Neil
- Esperienza